This Week's Rocket Stocks Portfolio Update
Earnings are always tough to game, that is why I geared this week's Rocket Stock portfolio and column around companies that have international exposure.
Eaton
(ETN) - Get Report
, one of the stocks I featured as an earnings play this week, handily beat earnings before the market open Monday but lowered its fourth-quarter guidance numbers, sending shares 4.5% lower in premarket trading that day.
In my book
, I discuss and show how such gaps down provide great buying opportunities, especially after the companies beat earnings estimates. Sure enough, Friedman Billings Ramsey the next day
upgraded Eaton
to outperform, sending shares higher. With shares up about 5% so far this week, I would sell to cash in this gain.
I also recommended
CSX Corp
(CSX) - Get Report
as an earnings play. Shares are up 6% since I wrote about CSX on Monday as third-quarter profit rose 24% and earnings beat estimates. CSX also made headlines after the companny received a letter from
The Children's Investment Fund
, an activist shareholder investor.
The fund laid into CSX's chief executive, saying "Michael Ward has been the highest compensated CEO in the rail industry over the past two years, despite CSX being operationally outperformed by its peers." I like Ward, especially after these latest earnings numbers, but the fund is right about his compensation. I would lock in this 6% gain with CSX here.
Another pick,
Intuitive Surgical
(ISRG) - Get Report
is down about 5% since the start of the week, but I would still hold on to it as an earnings play. The medical-equipment company reports after the close tomorrow.
I still like
SanDisk
(SNDK)
ahead of its quarterly report as well. Judging from the major technology companies that reported Tuesday night -
Yahoo!
(YHOO)
and
Intel
(INTC) - Get Report
for instance -- this beaten-up stock could rocket on Friday after the chipmaker reports Thursday afternoon.
I've added two more picks to this week's Rocket Stocks list as I believe both
Lundin Mining
(LMC)
and
Genzyme
(GENZ)
are well-managed companies that could take off anytime.
For further analyses on these and the rest of this week's picks, check out the
Rocket Stocks for the Week of Oct. 15th-19th
at Stockpickr.com.
At the time of publication, Altucher and/or his fund had no positions in stocks mentioned, although positions may change at any time.
James Altucher is president of Stockpickr LLC, a wholly owned subsidiary of TheStreet.com and part of its network of Web properties, and a managing partner at Formula Capital, an alternative asset management firm that runs a fund of hedge funds. He is also a weekly columnist for
The Financial Times
and the author of
Trade Like a Hedge Fund
,
Trade Like Warren Buffett
and
SuperCa$h
. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Altucher appreciates your feedback;
to send him an email.
TheStreet.com has a revenue-sharing relationship with Trader's Library under which it receives a portion of the revenue from purchases by customers directed there from TheStreet.com.